Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-1891 vs Levothyroxine in Primary Hypothyroidism
NCT05412979Phase 2Completed
- Sponsor
- Sention Therapeutics
- Start
- Apr 2022
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ST-1891 in primary hypothyroidism (PH) (2 arms), sponsored by Sention Therapeutics. Primary endpoint: Levothyroxine-to-ST-1891 dosing conversion factor at Week 52. Started Apr 2022; status: completed.
02
Drugs
ST-1891
03
Conditions
primary hypothyroidism (PH)
Beyond the preview
Go deeper on NCT05412979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05412979.